Stockscreener 앱 받기
22.64
2.56%
0.565
Neurogene Inc 주식(NGNE)의 최신 뉴스
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene files to sell 4M shares of common stock for holders - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out - AccessWire
Neurogene Inc. sees significant stock purchases by Samsara BioCapital - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene CEO Rachel McMinn acquires $968,999 in stock By Investing.com - Investing.com UK
Neurogene retains stock target, buy rating amid Rett syndrome trial data - Investing.com Canada
Insider Buying: Christine Cvijic Acquires 24,000 Shares of Neuro - GuruFocus.com
Neurogene president buys $491,400 in company stock By Investing.com - Investing.com Nigeria
Neurogene president buys $491,400 in company stock - Investing.com
Neurogene CEO Rachel McMinn acquires $968,999 in stock - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation - AccessWire
Neurogene retains stock target, buy rating amid Rett syndrome trial data By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Patient dies in Neurogene trial - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect - AccessWire
BMO Capital Markets Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week - MSN
Jennison Associates LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright - Defense World
Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ - Mugglehead
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation - AccessWire
Patient dies in Neurogene’s Phase I/II Rett syndrome trial - Yahoo Finance
Neurogene drops high-dose arm in Rett study after death - pharmaphorum
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial - Yahoo Finance
Neurogene reports patient death in Rett syndrome trial - Investing.com
Neurogene reports patient death in Rett syndrome trial By Investing.com - Investing.com Australia
Neurogene Adjusts Clinical Trial After Setback - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation - AccessWire
Leerink Partnrs Forecasts Reduced Earnings for Neurogene - MarketBeat
FY2024 EPS Estimates for Neurogene Cut by William Blair - MarketBeat
FY2024 EPS Estimates for Neurogene Raised by HC Wainwright - MarketBeat
Stifel stays positive on Neurogene stock amid regulatory clarity on Rett trial - Investing.com
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene price target lowered to $45 from $60 at BMO Capital - TipRanks
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
2.88%
2.65%
자본화:
|
볼륨(24시간):